Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aptose Biosciences, Inc. (APTOF : OTC)

• Company Description    Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $1.85 Daily Weekly Monthly 20 Day Moving Average: 17,643 shares Shares Outstanding: 2.55 (millions) Market Capitalization: $4.72 (millions) Beta: 0.77 52 Week High: $4.00 52 Week Low: $0.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.09% -2.37% 12 Week -6.09% -20.75% Year To Date -72.66% -77.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 66 WELLINGTON STREET WEST SUITE 5300 TD BANK TOWER BOX 48 - TORONTO,A6 M5K 1E6 CAN ph: 64-7479-9828 fax: 905-234-2120 ir@aptose.com http://www.aptose.com

• General Corporate Information    Officers William G. Rice - President; Chief Executive Officer and Chairman of Fletcher Payne - Senior Vice President and Chief Financial Officer Denis R. Burger - Director Carol G. Ashe - Director Erich M. Platzer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03835T408 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 2.55 Most Recent Split Date: 2.00 (0.03:1) Beta: 0.77 Market Capitalization: $4.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 88.09% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -216.18 12/31/24 - -227.05 Current Ratio 06/30/25 - - 03/31/25 - 1.10 12/31/24 - 2.14 Quick Ratio 06/30/25 - - 03/31/25 - 1.10 12/31/24 - 2.14 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -3.06 12/31/24 - -2.27 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©